İnce Başak, Phillips Matthew D, Dalton Bethan, Irish Madeleine, Webb Hannah, Mercado Daniela, McCombie Catherine, Zenasni Zohra, Shearer James, Potts Laura, Peachey Gemma, Au Katie, Kern Nikola, Clark-Stone Sam, Connan Frances, Johnston A Louise, Lazarova Stanimira, Zadeh Ewa, Tomlin Sophie, Battisti Francesca, Ioannidis Konstantinos, Newell Ciarán, Pathan Tayeem, Wales Jackie, Cashmore Rebecca, Marshall Sandra, Arcelus Jon, Robinson Paul, Byford Sarah, Landau Sabine, Lawrence Vanessa, Himmerich Hubertus, Treasure Janet, Schmidt Ulrike
Centre for Research in Eating and Weight Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
The Oxford Institute of Clinical Psychology Training and Research, University of Oxford, Oxford, UK.
Health Technol Assess. 2025 Feb;29(3):1-37. doi: 10.3310/FTJP6744.
A substantial proportion of anorexia nervosa patients require intensive treatments, commonly inpatient or day-patient treatment. The relative merits of these treatments for adults with anorexia nervosa are unknown. Therefore, a trial investigating the clinical effectiveness and cost-effectiveness of inpatient treatment-as-usual versus a stepped-care day-patient approach in adults with anorexia nervosa (DAISIES) was commissioned. This trial terminated prematurely due to poor recruitment, mainly resulting from COVID-19's impact on service provision.
We describe the rationale, methods and available outcomes of the DAISIES trial. Reasons behind the trial's failure and implications for future research are investigated.
A two-arm multicentre open-label parallel-group non-inferiority randomised controlled trial, evaluating the effectiveness, acceptability and cost-effectiveness of two intensive treatments for adults with severe anorexia nervosa.
Specialist eating-disorder services in the United Kingdom with inpatient and/or day-patient treatment facilities.
Adults (age 17 +) with severe anorexia nervosa (body mass index ≤ 16 kg/m) requiring intensive treatment and (optionally) their carers. Intended sample size: 386.
Inpatient treatment-as-usual and a stepped-care day-patient treatment approach (with the option of initial inpatient treatment for medical stabilisation).
The primary outcome was body mass index at 12 months post randomisation. Qualitative interviews conducted during the trial included semistructured interviews to investigate patients', families' and clinicians' views on treatments.
During the 16-month recruitment period (November 2020 to March 2022), 53 patients were approached. Of these, 15 were enrolled and randomly allocated to the inpatient treatment-as-usual ( = 7) or day-patient treatment ( = 8) treatment arms. All participants were female with a mean (standard deviation) age of 24.8 (9.1) years and a mean (standard deviation) body mass index of 14.4 (1.6) kg/m. Patients' body mass indexes had increased similarly in both groups at 12 months. Participants perceived the stepped-care day-patient treatment approach to be more acceptable than inpatient treatment-as-usual. Qualitative interviews with patients, carers and clinicians suggested valued (e.g. multidisciplinary provision of care) and disliked (e.g. perceived over-focus on weight gain) aspects of treatment. Investigation of the reasons behind the trial's failure revealed strong treatment preferences among patients as the most common reason for non-participation, alongside the impact of COVID-19 on service provision.
The main trial questions could not be answered due to low participant numbers.
No conclusions can be drawn concerning the clinical and cost-effectiveness of inpatient treatment-as-usual or stepped-care day-patient treatment. The day-patient treatment approach was perceived more positively by patients and carers. Service-related (e.g. reduced clinician time for research), patient-related (e.g. treatment preferences) and wider systemic factors (e.g. reduced service capacity and patient throughput nationally during COVID-19) seem to have contributed to the failure of the DAISIES trial.
Despite the trial's failure, the need to investigate the effectiveness and experience of intensive treatments of adult anorexia nervosa remains. Alternative trial designs incorporating patient preferences and investigating community-based intensive treatment options have potential to improve acceptability and recruitment.
This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number HTA 17/123/03.
相当一部分神经性厌食症患者需要强化治疗,通常是住院治疗或日间住院治疗。这些治疗方法对成年神经性厌食症患者的相对优势尚不清楚。因此,委托开展了一项试验,以调查常规住院治疗与成人神经性厌食症阶梯式日间住院治疗方法(DAISIES)的临床有效性和成本效益。由于招募情况不佳,该试验提前终止,主要原因是新冠疫情对服务提供的影响。
我们描述DAISIES试验的基本原理、方法和可用结果。调查试验失败的原因及其对未来研究的影响。
一项双臂多中心开放标签平行组非劣效性随机对照试验,评估两种强化治疗对成年重度神经性厌食症患者的有效性、可接受性和成本效益。
英国提供住院和/或日间住院治疗设施的专业饮食失调服务机构。
年龄在17岁及以上、患有重度神经性厌食症(体重指数≤16kg/m²)且需要强化治疗的成年人以及(可选)他们的照顾者。预期样本量为386。
常规住院治疗和阶梯式日间住院治疗方法(可选择初始住院治疗以实现医疗稳定)。
主要结局指标是随机分组后12个月时的体重指数。试验期间进行的定性访谈包括半结构化访谈,以调查患者、家属和临床医生对治疗的看法。
在16个月的招募期(2020年11月至2022年3月)内,共联系了53名患者。其中,15名患者入组并被随机分配到常规住院治疗组(n=7)或日间住院治疗组(n=8)。所有参与者均为女性,平均(标准差)年龄为24.8(9.1)岁,平均(标准差)体重指数为14.4(1.6)kg/m²。两组患者在12个月时的体重指数增加情况相似。参与者认为阶梯式日间住院治疗方法比常规住院治疗更可接受。对患者、照顾者和临床医生的定性访谈表明了治疗中受重视的方面(如多学科护理服务)和不受欢迎的方面(如过度关注体重增加)。对试验失败原因的调查显示,患者强烈的治疗偏好是最常见的未参与原因,同时新冠疫情对服务提供也有影响。
由于参与者数量较少,主要试验问题无法得到解答。
关于常规住院治疗或阶梯式日间住院治疗的临床和成本效益无法得出结论。患者和照顾者对日间住院治疗方法的看法更为积极。与服务相关的因素(如减少临床医生用于研究的时间)、与患者相关的因素(如治疗偏好)以及更广泛的系统性因素(如新冠疫情期间全国服务能力和患者流量下降)似乎都导致了DAISIES试验的失败。
尽管试验失败,但仍有必要调查成年神经性厌食症强化治疗的有效性和体验。纳入患者偏好并研究基于社区的强化治疗方案的替代试验设计有可能提高可接受性和招募率。
本摘要介绍了由英国国家卫生与保健研究所(NIHR)卫生技术评估计划资助的独立研究,资助编号为HTA 17/123/03。